HUE028008T2 - sGC stimulátorok vagy sGC aktivátorok önmagukban és PDE5 inhibitorokkal való kombinációban cisztás fibrózis kezelésére - Google Patents
sGC stimulátorok vagy sGC aktivátorok önmagukban és PDE5 inhibitorokkal való kombinációban cisztás fibrózis kezelésére Download PDFInfo
- Publication number
- HUE028008T2 HUE028008T2 HUE11701683A HUE11701683A HUE028008T2 HU E028008 T2 HUE028008 T2 HU E028008T2 HU E11701683 A HUE11701683 A HU E11701683A HU E11701683 A HUE11701683 A HU E11701683A HU E028008 T2 HUE028008 T2 HU E028008T2
- Authority
- HU
- Hungary
- Prior art keywords
- methyl
- phenyl
- sgc
- pyridine
- pyrazolo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
Claims (5)
- Szabadalmi igénypontok !. Az alábbiak köréből választott sOC stimulator vagy aktiváíor alkalmazása 2-fl-|2-ílaod>«!ízil}-l bí~pir^oloí3,4^]pírídín-3-!Í]“5~{4-mo.rfoyaiI)~4,6-pirim:kimslsa;mm(l), 2«| 142-luofbeííZi}“ 1 Bitirazolöf 3 ^Iptrióm-a -íll-5<4^rldmíI)-4~pIrimidÍBamk (2), metil"4,6-díamsöO"24H2~flüorbeKzil)'lH^kszo!b|3,4~b]pirídm-3-il]-'5~ pi rí m i d i n i 1{ mets l)kar barnát (3), meti!-4,b-diaBiis0-2-|H2-flui)rbeKzi;l)-'lli-piriizoloiP<4-&]pifii!5»-3-iIi'-5'-pIrimid»iikarba5wal(4), 3~(4-a:mino~5-eiklopropllpmmMiii-2-il)-l-(2--ilüorbe?5zil)»lB«pifaz0lö{3,4~b]piridia (4ak $4iför-2~(5-kbAio&~2-szu!lbmlamiftö~N44-{íborÍAlm“4^sz«lfóöjl|-fei5Íl)--beBzaí35Íd:0átHöm®6 (% :2-(4-kl0r-fenHszulfo«ilamm0)-4>5^»»*iö3ii*N*(4“(tiorooFfoIin-4"Saaifonii)-reniI)“benzamid {1%. •és/vagy 4-4{(4-karb0xibmii}[2»(2-{(4-{2-fe«ifetil} benzil] benzoesav (S), !-{ő~[S--kÍ0r--2-(|4-teíS2-4-}trifluormetíl}cíkl0bexil|feeozÍ|:QM}feííi;Í| plrMim24i}~5~ (tnOuonrseisl)- 3 H-pfeazöI-d-karbönsav (8), l"f6“C2*(2“aíeíö*4"C44rsfluormet0sifeail)be0zitef)-fei)pSFMm-2-íl]-5-iríOö0rmetiIpirazo3-4-karbonsav (9), 1 [6-{3,4-dikl0rferbib2--piridiBÜ--5-{trif1in:aiBet'd)·· 1 U-pimaM-karfe^Bsay {1 Ok 1 -(|243-klb^5-{P'i&om5eíIÍ)fcml]“S-rn«ííl-l;3-bazöí-4-s3}metíl}" IHrfîârazoM-kaîèoasay (! 1% 4-( {2-[3-{trifiuormeii)fën;îl]- 3 34iazoI-441]:metií}b®n2oesav' (12), i4{2-[2-fhmr-3-(írí3íuer:meíl3)fei3]-5mieti3-3 J4iaz0l-443}a^etil)4M":piraE0l“4-kafbos3sav (13) esszíás fibrozís fCP) kezelésére szolgáló gyógyszer előállítására.
- 2. Egy az alábbiak köréből választott sGC stimtdátor 3, igénypont szerioíialkalmazása mőti3-4,ő-áÍaabí50-2~fl~(2-fluorbeozil)-lB~píFazolep,4-bJpkícf3a-3~IIl-S~ p]rbnidi»iKmetil)karbamát0), metH-4.6-diam ίηο-2-f 1 ~(2~fl«erbenzíl}-1ll4Mtazolo[3,44%lndmG4!]-5-pmrnMimlkarbaniát (4),. 3^4-amíoe-S-cíklopfOpiipSFÍ:midm-243)~ 1 ”(2~Saorbenzíl)í H-pimzelo[3,4~b)pirym (4á> eásztás fibrózís (CF) kezelésére szolgáié gyógyszer előállítására.
- 3. Meöl-4,b-di:amioo-2-f 3 42~ieorbenziI)~ 3 H~plr^o3ö|3,4:-l^pirMí«-3~il3-5~pirí^idíríil<írí€íll>-karbamáí (3) Iés 2. igénypont szerkói alkalmazása eisztás Sbrózis (CF) kezelésére szolgáló gyógyszer előállítására. 4v 3-(4-aiíimo~5'Cáklopropí3pírimidin-2-il)-1 -(2-íftm?benzlI)l B~pirazolof354~b|píndm (4a) az 1. és 2. Igénypont szeresd alkalmazása eisztás ílbrőzis (CF) kezelésére szolgáló gyógyszer előállítására,
- 5. Legalább egy' az 1 -4. igénypontok bármelyike szériái vegyületet tartalmazó gyógyászait készítmény eisztás fíbrózísbass (CF) szenvedő betegeknél való alkalmazásra. 4 Az alábbiak köréből választott legalább egy sGC stámdátor vagy stóvátisr 2-[l~(2-fíoorbenzit}-1 H*pka2öM3,4-blpkMú^3-Ml*544>m«*follBÍM»4-prí!a:MÍ0dl^níií CG* 2- | I -(2~ßoorbenrii}-1: H-plrazoio[3 ,4-!rifdridin-3~ilJ~5-(4-piridmi!)~4-pirim Minarnio: (2), 5«eíi^,6-diarain«-24G(2-fí«or|5eri2;iÍ)-l:H~plra2;ölo[3,4“l3|py£liíí“3"3l]--S-pirím:í<IÍníl(3Tíel:I!)~ karbamát (3), ä^eii:M,6^dlamiB«>'2-[l”(2-ßworbeßÄil>IH“pira^Qfep54-blp5rldi^-il]-S"pirsmldiHllk:arbamai(4}! 3- (4-amIno~3-cíklopropilpirimíclií^2-ll)-1 -(2-0aorberíxiI) 1 H-p!razoio!3,4-b]p!ridm (4a), 5~klô^2^S-klôrôoië«"2-szullb?illamis50-N-{4-(m<)rfbli5î-4”SaJllG«si)”fèrï3l)-te2amid náíritrorsó (6), 2^4-kiöf-l^ii^lfemlam-feo>4,5-dímetoxi-14-(4-f iömörfebn-4^zallball)-f©rill)-beö2a®id: {7}, és/v-agy 444(4-karboxíbutíl)|2-(2-||4-{2-feí5Íletll) beozil| oxr|IS3dl)e4il|aaxino|rneisl) benzoesav (5), l-{6“|5-klbr-2-({44ra®sz-4-|triia<>mjeiil}dkfobexM]beKzlt|oxt)feall|pkli£li«-2-il}-5-(trsf!uonöetil>-I H-pirazoî-4-karboasav (%% Ι-Ι^^^-ΜδΐίΙ^^-ίοΙ^οοΗδΐοχί&βΙβΙίεΐΐζίΙίϊχί^ίείίΐ^ρίΓΐίΙϊΒ^-ΐ^-ΐ-ίΓΐΐΒβΓίτ^ΙΙ-ρίΓδζοΙ^-karbonsav (9), 1 [ó-(3,4~dikfórlén íl)-2-pIrídfeúl-S-{trMaom5etiI)-1 H-pirazo!~4-karbonsav (.1.6¾ l-({2-|23-klőr-54:íTífluoeHMil)fesll|-5-Tneííl-i3"b^ol-4-íl}íaeííí|-l1í-píraz0l-4-l:arbonsav (il), 44 {243 -ííriíl u onnét! isién 111-1,3-uazol-4-il} meíii}benzoesav ( 12), I -4 {2- [2-0 uor-3 4írsí1 uorrrsei ií}:lesil|--5-ffietl I-1,3 -ilazol~4-it} mets1)-1M-pirazoM-karbonsav ( 13 ) kombinálása Yardeoafií, Sildenafil Tadaiaíil, Udenafik Dasaníafd, Avasai!!, Mirodenafll, LodersafsL OK 369,603, OK 371.866, SLx21öl és LÄS34I79 koréból választóit Í»D15 inhibitorral ahol a kombináció 0,01 - LÖ mg sGC sünndáíost vagy aktivátort és 2,5-20 mg PDE5 inhibitort tartalmaz. 7, A 6. igénypont szerinti kombináció, ahol m sGC sthimiátor metil-4,6-diamiöo-2~[ 1 -(2-titiorbenzii)-I l1-pOTzofe|3,4-b]piridm“3-r!l-5-pinm1dml5--(metd3karhmsai (3) vagy metii-456~diamino-2-f 1 -42-fluorbestzil}- 1 H“pirazolo[3,4-b]piridin~3-il]-5-pirÍHtidinilkarbamát (4). 8, .4 6, és 7, igénypont szerinti kombináció, ràol a IPDBS inbibrtor Vardenatil vagy Sildenafil 9.4 6-8, igénypontok szerinti kombináció gyógyszerként való alkalmazásra. 16. 4 6-9, igénypontok szerinti kombináció alkalmazása cisztás fíbrőzis (CF) kezelésére szolgáló gyógyszer előállítására. 11. 4 6-9. igénypontok szerinti kombináció alkalmazása eisziás tihrőzisban (CF) szenvedő betegeknél való alkalmazásra.
- 12. Gyógyászati készítmény, amely legalább egy, a. 64 igénypontok szerbit kombinációt tartalmaz.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10152727 | 2010-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028008T2 true HUE028008T2 (hu) | 2016-11-28 |
Family
ID=43759663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11701683A HUE028008T2 (hu) | 2010-02-05 | 2011-02-03 | sGC stimulátorok vagy sGC aktivátorok önmagukban és PDE5 inhibitorokkal való kombinációban cisztás fibrózis kezelésére |
Country Status (32)
Country | Link |
---|---|
US (1) | US20130035340A1 (hu) |
EP (1) | EP2531187B1 (hu) |
JP (2) | JP6143461B2 (hu) |
KR (1) | KR101793304B1 (hu) |
CN (3) | CN104800219A (hu) |
AU (1) | AU2011212521B2 (hu) |
BR (1) | BR112012019666A2 (hu) |
CA (1) | CA2788969C (hu) |
CL (1) | CL2012002173A1 (hu) |
CR (1) | CR20120408A (hu) |
CY (1) | CY1116878T1 (hu) |
DK (1) | DK2531187T3 (hu) |
EA (1) | EA025177B1 (hu) |
ES (1) | ES2548394T3 (hu) |
HK (1) | HK1212892A1 (hu) |
HR (1) | HRP20151187T1 (hu) |
HU (1) | HUE028008T2 (hu) |
IL (1) | IL221012B (hu) |
MA (1) | MA33984B1 (hu) |
MX (1) | MX342944B (hu) |
MY (2) | MY159697A (hu) |
NZ (1) | NZ601612A (hu) |
PL (1) | PL2531187T3 (hu) |
PT (1) | PT2531187E (hu) |
RS (1) | RS54336B1 (hu) |
SG (1) | SG182819A1 (hu) |
SI (1) | SI2531187T1 (hu) |
SM (1) | SMT201500286B (hu) |
TN (1) | TN2012000397A1 (hu) |
UA (1) | UA112962C2 (hu) |
WO (1) | WO2011095534A1 (hu) |
ZA (1) | ZA201205532B (hu) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800219A (zh) * | 2010-02-05 | 2015-07-29 | 阿德弗里奥药品有限责任公司 | 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂 |
US10189856B2 (en) | 2010-05-26 | 2019-01-29 | Adverio Pharma Gmbh | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
EP2687210A1 (de) * | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen |
EP2594270A3 (en) * | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
DK2892891T3 (da) * | 2012-09-07 | 2019-10-14 | Boehringer Ingelheim Int | Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer |
WO2015011086A1 (en) * | 2013-07-25 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
JP2016540017A (ja) | 2013-12-11 | 2016-12-22 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激物質 |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
AU2015292833B2 (en) | 2014-07-22 | 2019-11-28 | Boehringer Ingelheim International Gmbh | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
US20170291889A1 (en) | 2014-09-17 | 2017-10-12 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US10316020B2 (en) | 2015-12-18 | 2019-06-11 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
WO2018112149A1 (en) | 2016-12-16 | 2018-06-21 | Cystic Fibrosis Foundaton Therapeutics Inc. | Bycyclic heteroaryl derivatives as cftr potentiators |
CN110305125B (zh) * | 2019-06-06 | 2021-09-03 | 山东新华制药股份有限公司 | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
CZ302691B6 (cs) * | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
US20080081816A1 (en) * | 2006-10-03 | 2008-04-03 | Kaohsiung Medical University | Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3 |
EP2144605A1 (en) * | 2007-05-12 | 2010-01-20 | Bayer HealthCare AG | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS |
AU2008296974B2 (en) * | 2007-09-06 | 2013-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
WO2009071504A1 (en) * | 2007-12-03 | 2009-06-11 | Smithkline Beecham Corporation | 2,6-disubstituted pyridines as soluble guanylate cyclase activators |
US8461348B2 (en) | 2008-04-04 | 2013-06-11 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
WO2009149278A1 (en) * | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CN104800219A (zh) * | 2010-02-05 | 2015-07-29 | 阿德弗里奥药品有限责任公司 | 用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂 |
-
2011
- 2011-02-03 CN CN201510259173.XA patent/CN104800219A/zh active Pending
- 2011-02-03 BR BR112012019666A patent/BR112012019666A2/pt not_active Application Discontinuation
- 2011-02-03 EA EA201290702A patent/EA025177B1/ru not_active IP Right Cessation
- 2011-02-03 US US13/577,135 patent/US20130035340A1/en not_active Abandoned
- 2011-02-03 AU AU2011212521A patent/AU2011212521B2/en not_active Ceased
- 2011-02-03 DK DK11701683.2T patent/DK2531187T3/en active
- 2011-02-03 JP JP2012551615A patent/JP6143461B2/ja not_active Expired - Fee Related
- 2011-02-03 PL PL11701683T patent/PL2531187T3/pl unknown
- 2011-02-03 MY MYPI2012003529A patent/MY159697A/en unknown
- 2011-02-03 HU HUE11701683A patent/HUE028008T2/hu unknown
- 2011-02-03 KR KR1020127020467A patent/KR101793304B1/ko active IP Right Grant
- 2011-02-03 ES ES11701683.2T patent/ES2548394T3/es active Active
- 2011-02-03 WO PCT/EP2011/051532 patent/WO2011095534A1/en active Application Filing
- 2011-02-03 PT PT117016832T patent/PT2531187E/pt unknown
- 2011-02-03 MX MX2012009011A patent/MX342944B/es active IP Right Grant
- 2011-02-03 CN CN2011800083494A patent/CN102770133A/zh active Pending
- 2011-02-03 SI SI201130648T patent/SI2531187T1/sl unknown
- 2011-02-03 RS RS20150716A patent/RS54336B1/en unknown
- 2011-02-03 MA MA35118A patent/MA33984B1/fr unknown
- 2011-02-03 CA CA2788969A patent/CA2788969C/en not_active Expired - Fee Related
- 2011-02-03 NZ NZ601612A patent/NZ601612A/en not_active IP Right Cessation
- 2011-02-03 SG SG2012056743A patent/SG182819A1/en unknown
- 2011-02-03 CN CN201711274967.9A patent/CN107929271A/zh active Pending
- 2011-02-03 EP EP11701683.2A patent/EP2531187B1/en active Active
- 2011-02-04 MY MYPI2012003528A patent/MY160856A/en unknown
- 2011-03-02 UA UAA201210468A patent/UA112962C2/uk unknown
-
2012
- 2012-07-18 IL IL221012A patent/IL221012B/en not_active IP Right Cessation
- 2012-07-23 ZA ZA2012/05532A patent/ZA201205532B/en unknown
- 2012-08-03 CL CL2012002173A patent/CL2012002173A1/es unknown
- 2012-08-03 TN TNP2012000397A patent/TN2012000397A1/en unknown
- 2012-08-06 CR CR20120408A patent/CR20120408A/es unknown
-
2015
- 2015-10-30 CY CY20151100972T patent/CY1116878T1/el unknown
- 2015-11-05 HR HRP20151187TT patent/HRP20151187T1/hr unknown
- 2015-11-19 SM SM201500286T patent/SMT201500286B/it unknown
-
2016
- 2016-01-26 HK HK16100823.5A patent/HK1212892A1/zh unknown
- 2016-05-09 JP JP2016093876A patent/JP6270907B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2531187B1 (en) | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
US10265314B2 (en) | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | |
US20080318982A1 (en) | Pharmaceutical Combination for the Treatment of Luts | |
CN108430475B (zh) | 用于治疗慢性咳嗽的奥维匹坦 | |
KR20180002657A (ko) | 전신 경화증 (SSc)에 수반되는 수족지 궤양 (DU)의 치료를 위한 sGC 자극제, sGC 활성화제 단독 및 PDE5 억제제와의 조합물의 용도 | |
US20080261995A1 (en) | Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor | |
CA2604295A1 (en) | Roflumilast for the treatment of pulmonary hypertension | |
MXPA04010951A (es) | Nueva combinacion. | |
JP2005531627A (ja) | 新規混合医薬 | |
US20040132731A1 (en) | Novel combination | |
WO2005042022A2 (en) | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist |